|1.||McMurray, John J V: 17 articles (09/2015 - 03/2005)|
|2.||Tomita, Dianne: 17 articles (11/2012 - 08/2002)|
|3.||Pfeffer, Marc A: 15 articles (09/2015 - 03/2005)|
|4.||Solomon, Scott D: 14 articles (09/2015 - 03/2005)|
|5.||Vansteenkiste, Johan: 12 articles (04/2013 - 08/2002)|
|6.||Rossi, Greg: 12 articles (10/2007 - 11/2003)|
|7.||Lefebvre, Patrick: 10 articles (01/2012 - 01/2006)|
|8.||Ivanovich, Peter: 9 articles (09/2015 - 03/2005)|
|9.||Lewis, Eldrin F: 9 articles (09/2015 - 07/2009)|
|10.||Glaspy, John: 9 articles (04/2013 - 10/2002)|
07/01/2009 - "With several-fold more patient-years and a placebo arm, TREAT will provide a robust estimate of the safety and efficacy of darbepoetin alfa and generate prospective data regarding the risks of major cardiovascular and renal events in a contemporarily managed cohort of patients with type 2 diabetes, CKD, and anemia."
06/01/2008 - "Darbepoetin alfa is an erythropoiesis-stimulating agent that has been shown to be effective in treating anemia in patients with CKD (but not on dialysis) when administered using extended-dosing regimens. "
09/01/2006 - "The objective of this study was to determine if darbepoetin alfa administered at a reduced dosing frequency relative to the prior rHuEpo regimen is an effective and safe alternative for treating renal anemia in patients undergoing dialysis. "
05/01/2008 - "Darbepoetin alfa has the potential to simplify the treatment of CKD anemia with many advantages, including infrequent dosing, improved patient convenience and compliance, and decreased healthcare resource utilization. "
01/01/2005 - "Darbepoetin alfa is generally well tolerated, and clinical trials of 20-52 weeks' duration have demonstrated the efficacy of subcutaneous and intravenous administration at 1- or 2-week intervals in the initial treatment of anemia associated with CKD both in dialysis patients and in patients not yet on dialysis. "
09/01/2009 - "We report results from a multicenter, randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy and safety of fixed-dose Q3W darbepoetin alfa in patients with a wide variety of tumor types who experienced CIA. "
01/01/2006 - "A subsequent dose-finding study of once-every-3-week darbepoetin alfa treatment showed that the drug was effective and well-tolerated in anaemic cancer patients and reduced the need for transfusions at all doses compared with placebo. "
05/01/2011 - "To evaluate adherence to European Organisation for Research and Treatment of Cancer (EORTC) and European Summary of Product Characteristic (SmPC) guidance on recommended haemoglobin (Hb) values in routine clinical practice use of darbepoetin alfa (DA) in cancer patients internationally. "
07/01/2009 - "Darbepoetin alfa users tended to be younger, had more comorbidities, and had advanced cancer (all p < 0.001). "
09/01/2008 - "Effects of aerobic exercise training in anemic cancer patients receiving darbepoetin alfa: a randomized controlled trial."
|3.||Kidney Diseases (Kidney Disease)
06/01/2007 - "Data from several randomized studies have shown that darbepoetin alfa is effective in maintaining haemoglobin levels when administered (subcutaneously, intravenously or both) every 2 weeks in dialysis patients, and every 2 weeks or monthly in patients with chronic kidney disease not yet receiving dialysis. "
06/01/2012 - "Darbepoetin alfa (DA) has been shown to be an effective treatment of anaemia in patients with chronic kidney disease (CKD) not on dialysis (NoD). "
10/01/2006 - "The efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis."
06/01/2012 - "An observational cohort study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: the EXTEND study."
04/01/2011 - "Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial."
04/01/2011 - "Darbepoetin alfa confers a consistent, but small, improvement in fatigue and overall quality of life but not in other domains. "
08/21/2002 - "Patients receiving darbepoetin alfa required fewer transfusions (27% versus 52%; mean difference = 25%; 95% confidence interval [CI] = 14% to 36%; P<.001), required fewer units of blood (0.67 versus 1.92; mean difference = 1.25, 95% CI = 0.65 to 1.84; P<.001), had more hematopoietic responses (66% versus 24%; mean difference = 42%; 95% CI = 31% to 53%; P<.001), and had better improvement in FACT-Fatigue scores (56% versus 44% overall improvement; 32% versus 19% with >or=25% improvement; mean difference = 13%; 95% CI = 2% to 23%, P =.019) than patients receiving placebo. "
11/19/2009 - "There was only a modest improvement in patient-reported fatigue in the darbepoetin alfa group as compared with the placebo group. "
04/01/2006 - "Efficacy of darbepoetin alfa in alleviating fatigue and the effect of fatigue on quality of life in anemic patients with lymphoproliferative malignancies."
04/01/2004 - "Darbepoetin alfa also improved fatigue compared with placebo in both haemoglobin categories. "
12/01/2008 - "Darbepoetin is, however, currently being tested in a large-scale, phase III morbidity and mortality trial, the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF) which should contribute important information of the safety and efficacy of ESAs in this syndrome. "
05/01/2006 - "Darbepoetin alfa increased haemoglobin levels in heart failure patients and improved some aspects of quality of life compared to placebo. "
08/01/2005 - "The erythropoiesis stimulating protein, darbepoetin alfa, increased haemoglobin levels, improved quality of life and showed a trend for improved exercise duration in anaemic patients with symptomatic chronic heart failure. "
03/01/2013 - "This report describes the baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF) which is testing the hypothesis that anaemia correction with darbepoetin alfa will reduce the composite endpoint of death from any cause or hospital admission for worsening heart failure, and improve other outcomes. "
03/01/2013 - "Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF)."
|2.||Epoetin Alfa (Epogen)
|3.||darbepoetin alfa (Aranesp)
|8.||continuous erythropoietin receptor activator
|1.||Drug Therapy (Chemotherapy)
|3.||Renal Dialysis (Hemodialysis)